{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:27:48Z","timestamp":1790872068495,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/100011997","name":"Fundaci\u00f3n SEEN","doi-asserted-by":"publisher","award":["Financial support for clinical research"],"award-info":[{"award-number":["Financial support for clinical research"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/100011997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s12020-022-03029-4","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T11:05:04Z","timestamp":1646996704000},"page":"687-696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Evolution of the cardiometabolic profile of primary hyperaldosteronism patients treated with adrenalectomy and with mineralocorticoid receptor antagonists: results from the SPAIN-ALDO Registry"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-0072","authenticated-orcid":false,"given":"Marta","family":"Araujo-Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Paja Fano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marga","family":"Gonz\u00e1lez Boillos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Pla Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eider","family":"Pascual-Corrales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Garc\u00eda Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Parra Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Mart\u00edn","family":"Rojas-Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Gabriel","family":"Ruiz-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Vicente Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"G\u00f3mez Hoyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1igo","family":"Garc\u00eda Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"D\u00edaz Guardiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jes\u00fas","family":"Garc\u00eda Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina M.","family":"Perdomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia A.","family":"Hanzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"3029_CR1","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"G.P. Rossi, G. Bernini, C. Caliumi, G. Desideri, B. Fabris, C. Ferri et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J. Am. Coll. Cardiol. 48, 2293\u20132300 (2006) https:\/\/doi.org\/10.1016\/j.jacc.2006.07.059","journal-title":"J. Am. Coll. Cardiol."},{"key":"3029_CR2","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, J.J. Mourad et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45, 1243\u20131248 (2005) https:\/\/doi.org\/10.1016\/j.jacc.2005.01.015","journal-title":"J. Am. Coll. Cardiol."},{"key":"3029_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","volume":"48","author":"GP Rossi","year":"2006","unstructured":"G.P. Rossi, G. Bernini, G. Desideri, B. Fabris, C. Ferri, G. Giacchetti et al. Renal damage in primary aldosteronism: results of the PAPY study. Hypertension 48, 232\u2013238 (2006) https:\/\/doi.org\/10.1161\/01.HYP.0000230444.01215.6a","journal-title":"Hypertension"},{"key":"3029_CR4","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","volume":"50","author":"C Catena","year":"2007","unstructured":"C. Catena, G. Colussi, R. Lapenna, E. Nadalini, A. Chiuch, P. Gianfagna et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 50, 911\u2013918 (2007). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.095448","journal-title":"Hypertension"},{"key":"3029_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12020-021-02704-2","volume":"73","author":"M Fern\u00e1ndez-Arg\u00fceso","year":"2021","unstructured":"M. Fern\u00e1ndez-Arg\u00fceso, E. Pascual-Corrales, N. Bengoa Rojano, A. Garc\u00eda Cano, L. Jim\u00e9nez Mendiguch\u00eda, M. Araujo-Castro, Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study. Endocrine 73, 439\u2013446 (2021). https:\/\/doi.org\/10.1007\/s12020-021-02704-2","journal-title":"Endocrine"},{"key":"3029_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"S. Monticone, F. D\u2019Ascenzo, C. Moretti, T.A. Williams, F. Veglio, F. Gaita et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 6, 41\u201350 (2018). https:\/\/doi.org\/10.1016\/S2213-8587(17)30319-4","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3029_CR7","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","volume":"3","author":"GL Hundemer","year":"2018","unstructured":"G.L. Hundemer, G.C. Curhan, N. Yozamp, M. Wang, A. Vaidya, Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol. 3, 768\u2013774 (2018). https:\/\/doi.org\/10.1001\/jamacardio.2018.2003","journal-title":"JAMA Cardiol."},{"key":"3029_CR8","doi-asserted-by":"publisher","unstructured":"C.T. Pan, C.W. Liao, C.H.T sai, Z.W. Chen, L. Chen, C.S. Hung et al. Influence of different treatment strategies on new-onset atrial fibrillation among patients with primary aldosteronism: a nationwide longitudinal cohort-based study. J. Am. Heart Assoc. 9 (2020). https:\/\/doi.org\/10.1161\/JAHA.119.013699","DOI":"10.1161\/JAHA.119.013699"},{"key":"3029_CR9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/hypertensionaha.117.10596","volume":"71","author":"GP Rossi","year":"2018","unstructured":"G.P. Rossi, G. Maiolino, A. Flego, A. Belfiore, G. Bernini, B. Fabris et al. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension 71, 585\u2013591 (2018). https:\/\/doi.org\/10.1161\/hypertensionaha.117.10596","journal-title":"Hypertension"},{"key":"3029_CR10","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1210\/jc.2011-0138","volume":"96","author":"AH Ahmed","year":"2011","unstructured":"A.H. Ahmed, R.D. Gordon, N. Sukor, E. Pimenta, M. Stowasser, Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and\/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J. Clin. Endocrinol. Metab. 96, 2904\u20132911 (2011). https:\/\/doi.org\/10.1210\/jc.2011-0138","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3029_CR11","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","volume":"72","author":"GL Hundemer","year":"2018","unstructured":"G.L. Hundemer, G.C. Curhan, N. Yozamp, M. Wang, A. Vaidya, H. GL et al. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 72, 658\u2013666 (2018). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11568","journal-title":"Hypertension"},{"key":"3029_CR12","doi-asserted-by":"publisher","unstructured":"Y. Jing, K. Liao, R. Li, S. Yang, Y. Song, W. He et al. Cardiovascular events and all-cause mortality in surgically or medically treated primary aldosteronism: a Meta-analysis. J Renin-Angiotensin-Aldosterone Syst. 22, (2021). https:\/\/doi.org\/10.1177\/14703203211003781","DOI":"10.1177\/14703203211003781"},{"key":"3029_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","volume":"168","author":"C Catena","year":"2008","unstructured":"C. Catena, G.L. Colussi, E. Nadalini, A. Chiuch, S. Baroselli, R. Lapenna et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch. Intern. Med. 168, 80\u201385 (2008). https:\/\/doi.org\/10.1001\/archinternmed.2007.33","journal-title":"Arch. Intern. Med."},{"key":"3029_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cen.14351","volume":"94","author":"TH Puar","year":"2021","unstructured":"T.H. Puar, L.M. Loh, W.J. Loh, D.S.T. Lim, M. Zhang, P.T. Tan et al. Outcomes in unilateral primary aldosteronism after surgical or medical therapy. Clin. Endocrinol. 94, 158\u2013167 (2021). https:\/\/doi.org\/10.1111\/cen.14351","journal-title":"Clin. Endocrinol."},{"key":"3029_CR15","doi-asserted-by":"publisher","unstructured":"C. Catena, R. Lapenna, S. Baroselli, E. Nadalini, G.L. Colussi, M. Novello et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J. Clin. Endocrinol. Metab. (2006). https:\/\/doi.org\/10.1210\/jc.2006-0736","DOI":"10.1210\/jc.2006-0736"},{"key":"3029_CR16","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1210\/jc.2008-2245","volume":"94","author":"LA Sechi","year":"2009","unstructured":"L.A. Sechi, A.D.I. Fabio, M. Bazzocchi, A. Uzzau, C. Catena, Intrarenal hemodynamics in primary aldosteronism before and after treatment. J. Clin. Endocrinol. Metab. 94, 1191\u20131197 (2009). https:\/\/doi.org\/10.1210\/jc.2008-2245","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3029_CR17","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"B. Williams, G. Mancia, W. Spiering, E.A. Rosei, M. Azizi, M. Burnier et al. 2018 ESC\/ESHGuidelines for themanagement of arterial hypertension. J. Hypertens. 36, 1956\u20132041 (2018). https:\/\/doi.org\/10.1097\/HJH.0000000000001940","journal-title":"J. Hypertens."},{"key":"3029_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0272-6386(02)70104-2","volume":"39","author":"AS Levey","year":"2002","unstructured":"A.S. Levey, J. Coresh, K. Bolton, B. Culleton, K.S. Harvey, T.A. Ikizler et al. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39, 3\u201310 (2002).","journal-title":"Am. J. Kidney Dis."},{"key":"3029_CR19","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"J.W. Funder, R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 1889\u20131916 (2016). https:\/\/doi.org\/10.1210\/jc.2015-4061","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3029_CR20","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","volume":"38","author":"P Mulatero","year":"2020","unstructured":"P. Mulatero, S. Monticone, J. Deinum, L. Amar, A. Prejbisz, M.C. Zennaro et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J. Hypertens. 38, 1919\u20131928 (2020). https:\/\/doi.org\/10.1097\/HJH.0000000000002510","journal-title":"J. Hypertens."},{"key":"3029_CR21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","volume":"5","author":"TA Williams","year":"2017","unstructured":"T.A. Williams, J.W.M. Lenders, P. Mulatero, J. Burrello, M. Rottenkolber, C. Adolf et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 5, 689\u2013699 (2017). https:\/\/doi.org\/10.1016\/S2213-8587(17)30135-3","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3029_CR22","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.surg.2020.07.046","volume":"169","author":"O Picado","year":"2021","unstructured":"O. Picado, B.W. Whitfield, Z.F. Khan, M. Jeraq, J.C. Farr\u00e1, J.I. Lew, Long-term outcome success after operative treatment for primary aldosteronism. Surgery 169, 528\u2013532 (2021). https:\/\/doi.org\/10.1016\/j.surg.2020.07.046","journal-title":"Surgery"},{"key":"3029_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.7326\/0003-4819-135-4-200108210-00010","volume":"135","author":"AM Sawka","year":"2001","unstructured":"A.M. Sawka, J. Young, G.B. Thompson, C.S. Grant, D.R. Farley, C. Leibson et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann. Intern. Med. 135, 258\u2013261 (2001). https:\/\/doi.org\/10.7326\/0003-4819-135-4-200108210-00010","journal-title":"Ann. Intern. Med."},{"key":"3029_CR24","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1097\/HJH.0b013e3283060f0c","volume":"26","author":"E Letavernier","year":"2008","unstructured":"E. Letavernier, S. Peyrard, L. Amar, F. Zinzindohou\u00e9, B. Fiquet, P.F. Plouin, Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J. Hypertens. 26, 1816\u20131823 (2008). https:\/\/doi.org\/10.1097\/HJH.0b013e3283060f0c","journal-title":"J. Hypertens."},{"key":"3029_CR25","doi-asserted-by":"publisher","unstructured":"V.C. Wu, K.H. Huang, K.Y. Peng, Y.C.T. sai, C.H. Wu, S.M. Wang et al. Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population. Sci. Rep. 15 (2015). https:\/\/doi.org\/10.1038\/srep11396","DOI":"10.1038\/srep11396"},{"key":"3029_CR26","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/jch.12916","volume":"18","author":"JL Benham","year":"2016","unstructured":"J.L. Benham, M. Eldoma, B. Khokhar, D.J. Roberts, D.M. Rabi, G.A. Kline, Proportion of patients with hypertension resolution following adrenalectomy for primary aldosteronism: a systematic review and meta-analysis. J. Clin. Hypertens. 18, 1205\u20131212 (2016). https:\/\/doi.org\/10.1111\/jch.12916","journal-title":"J. Clin. Hypertens."},{"key":"3029_CR27","doi-asserted-by":"publisher","unstructured":"L. Marzano, G. Colussi, L.A. Sechi, C. Catena, Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies. Am. J. Hypertens. (2015). https:\/\/doi.org\/10.1093\/ajh\/hpu154","DOI":"10.1093\/ajh\/hpu154"},{"key":"3029_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","volume":"62","author":"GP Rossi","year":"2013","unstructured":"G.P. Rossi, M. Cesari, C. Cuspidi, G. Maiolino, M.V. Cicala, V. Bisogni et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 62, 62\u201369 (2013). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.01316","journal-title":"Hypertension"},{"key":"3029_CR29","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41440-019-0244-4","volume":"42","author":"M Satoh","year":"2019","unstructured":"M. Satoh, T. Maruhashi, Y. Yoshida, H. Shibata, Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism. Hypertens. Res. 42, 817\u2013824 (2019). https:\/\/doi.org\/10.1038\/s41440-019-0244-4","journal-title":"Hypertens. Res."},{"key":"3029_CR30","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1530\/EJE-19-0215","volume":"181","author":"B Lechner","year":"2019","unstructured":"B. Lechner, K. Lechner, D. Heinrich, C. Adolf, F. Holler, H. Schneider et al. Medical treatment of primary aldosteronism. Eur. J. Endocrinol. 181, R147\u2013R153 (2019). https:\/\/doi.org\/10.1530\/EJE-19-0215","journal-title":"Eur. J. Endocrinol."},{"key":"3029_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","volume":"6","author":"GL Hundemer","year":"2018","unstructured":"G.L. Hundemer, G.C. Curhan, N. Yozamp, M. Wang, A. Vaidya, Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 6, 51\u201359 (2018). https:\/\/doi.org\/10.1016\/S2213-8587(17)30367-4","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3029_CR32","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1530\/EJE-21-0018","volume":"185","author":"A K\u00f6hler","year":"2021","unstructured":"A. K\u00f6hler, A.L. Sarkis, D.A. Heinrich, L. M\u00fcller, L. Handgriff, S. Deniz et al. Renin, a marker for left ventricular hypertrophy, in primary aldosteronism: a cohort study. Eur. J. Endocrinol. 185, 663\u2013672 (2021). https:\/\/doi.org\/10.1530\/EJE-21-0018","journal-title":"Eur. J. Endocrinol."},{"key":"3029_CR33","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.4158\/EP-2020-0277","volume":"26","author":"Y Tezuka","year":"2020","unstructured":"Y. Tezuka, A.F. Turcu, Mineralocorticoid receptor antagonists decrease the rates of positive screening for primary aldosteronism. Endocr. Pract. 26, 1416\u20131424 (2020). https:\/\/doi.org\/10.4158\/EP-2020-0277","journal-title":"Endocr. Pract."},{"key":"3029_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1210\/jc.2017-01442","volume":"103","author":"M Velema","year":"2018","unstructured":"M. Velema, T. Dekkers, A. Hermus, H. Timmers, J. Lenders, H. Groenewoud, et al. Quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment. J. Clin. Endocrinol. Metab. 103, 16\u201324 (2018). https:\/\/doi.org\/10.1210\/jc.2017-01442","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3029_CR35","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3275\/7611","volume":"35","author":"G Bernini","year":"2012","unstructured":"G. Bernini, A. Bacca, V. Carli, D. Carrara, G. Materazzi, P. Berti et al. Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment. J. Endocrinol. Investig. 35, 274\u2013280 (2012). https:\/\/doi.org\/10.3275\/7611","journal-title":"J. Endocrinol. Investig."},{"key":"3029_CR36","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.bbadis.2010.08.005","volume":"1802","author":"JW Funder","year":"2010","unstructured":"J.W. Funder, M. Reincke, Aldosterone: a cardiovascular risk factor? Biochim. Biophys. Acta\u2014Mol. Basis Dis. 1802, 1188\u20131192 (2010). https:\/\/doi.org\/10.1016\/j.bbadis.2010.08.005","journal-title":"Biochim. Biophys. Acta\u2014Mol. Basis Dis."},{"key":"3029_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","volume":"66","author":"NK Hollenberg","year":"2004","unstructured":"N.K. Hollenberg, Aldosterone in the development and progression of renal injury. Kidney Int. 66, 1\u20139 (2004). https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00701.x","journal-title":"Kidney Int."},{"key":"3029_CR38","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"B. Pitt, N. Reichek, R. Willenbrock, F. Zannad, R.A. Phillips, B. Roniker et al. Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4e-left ventricular hypertrophy study. Circulation 108, 1831\u20131838 (2003). https:\/\/doi.org\/10.1161\/01.CIR.0000091405.00772.6E","journal-title":"Circulation"},{"key":"3029_CR39","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00380-018-1279-1","volume":"34","author":"H Fukuta","year":"2019","unstructured":"H. Fukuta, T. Goto, K. Wakami, T. Kamiya, N. Ohte, Effects of mineralocorticoid receptor antagonists on left ventricular diastolic function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Heart Vessels 34, 597\u2013606 (2019). https:\/\/doi.org\/10.1007\/s00380-018-1279-1","journal-title":"Heart Vessels"},{"key":"3029_CR40","doi-asserted-by":"publisher","unstructured":"W. Arlt, K. Lang, A.J. Sitch, A.S. Dietz, Y. Rhayem, I. Bancos et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight 2, (2017). https:\/\/doi.org\/10.1172\/JCI.INSIGHT.93136","DOI":"10.1172\/JCI.INSIGHT.93136"},{"key":"3029_CR41","doi-asserted-by":"publisher","unstructured":"Y. Tezuka, A.F. Turcu, Real-world effectiveness of mineralocorticoid receptor antagonists in primary aldosteronism. Front. Endocrinol 21, (2021). https:\/\/doi.org\/10.3389\/FENDO.2021.625457","DOI":"10.3389\/FENDO.2021.625457"},{"key":"3029_CR42","doi-asserted-by":"publisher","unstructured":"M.J.E. Kempers, J.W.M. Lenders, L. Van Outheusden, G.J. Van Der Wilt, L.J.S. Kool, A.R.M.M. Hermus et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann. Intern. Med. 151, (2009). https:\/\/doi.org\/10.7326\/0003-4819-151-5-200909010-00007","DOI":"10.7326\/0003-4819-151-5-200909010-00007"},{"key":"3029_CR43","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/MNM.0000000000000987","volume":"40","author":"MH Wu","year":"2019","unstructured":"M.H. Wu, F.H. Liu, K.J. Lin, J.H. Sun, S.T. Chen, Diagnostic value of adrenal iodine-131 6-beta-iodomethyl-19-norcholesterol scintigraphy for primary aldosteronism: a retrospective study at a medical center in North Taiwan. Nucl. Med. Commun. 40, 568\u2013575 (2019). https:\/\/doi.org\/10.1097\/MNM.0000000000000987","journal-title":"Nucl. Med. Commun."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03029-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03029-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03029-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T11:37:50Z","timestamp":1653997070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03029-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["3029"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03029-4","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]},"assertion":[{"value":"5 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Patient consent was waived due to the retrospective nature of the study. Only for patients who continued follow-up or prospectively included the informed consent was requested.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the Hospital Universitario Ram\u00f3n y Cajal. Madrid. Spain (approval date: 10th November 2020, code: ACTA 401).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}]}}